Achieve Life Sciences Inc.

Announcement: ACHV 8-K Special Filing

Form 8-K - Current report - Item 1.01 Item 9.01

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Error: Cannot read properties of null (reading '1')

Announcement: ACHV 10-K Annual Report

Analyst Summary: Achieve Life Sciences reported its financial results for Q4 and year-end 2022, which showed a total net loss of $42.4 million for the year. The company also reported recent highlights, including the completion of last subject visit for Phase 2 trial ORCA-V1, last subject dosed for Phase 3 trial ORCA-3, and patent granted by USPTO for new cytisinicline formulation. Management believes that cytisinicline has the potential to help millions of people overcome their dependence on nicotine. The company will continue to deliver on its key milestones in the year ahead, leveraging its 15 patents, 46 pending patents, and gross proceeds of approximately $18.9 million from a recent private placement. Achieve also plans to announce topline results from its ongoing trials in the second quarter of 2023. However, there is no assurance that any of these milestones will be achieved. Investors interested in this novel treatment for smoking cessation may also want to consider the ongoing global epidemic of nicotine addiction, which is responsible for more than eight million deaths worldwide and nearly half a million deaths annually in the United States. The FDA has not approved cytisinicline for any indication in the United States.

Form 8-K - Current report - Item 2.02 Item 9.01

$ACHV reports FY 2022 financial results & highlights, including updates on cytisinicline trials and patent grant

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ACHV 8-K Special Filing

Announcement: ACHV 8-K Special Filing

Announcement: ACHV 8-K Special Filing

Announcement: ACHV 8-K Special Filing

Announcement: ACHV 10-K Annual Report

Announcement: ACHV 10-K Annual Report

$ACHV reports FY 2022 financial results & highlights, including updates on cytisinicline trials and patent grant

$ACHV reports FY 2022 financial results & highlights, including updates on cytisinicline trials and patent grant

Announcement: ACHV 8-K Special Filing

Announcement: ACHV 8-K Special Filing

Announcement: ACHV SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACHV SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment